Immuron (IMRN) Asset Writedowns and Impairment (2016 - 2017)
Immuron's quarterly Asset Writedowns and Impairment came in at -$127500.4 in Q4 2017, down 25.1% year-on-year from -$170237.6 in Q4 2016, and down 25.1% quarter-over-quarter from -$101915.2 in Q4 2016.
Immuron has reported Asset Writedowns and Impairment for 2 years, with the latest figure at -$127500.4 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -127,500.44 |
| Dec 31, 2017 | -127,500.44 |
| Dec 31, 2016 | -101,915.21 |
| Dec 31, 2016 | -101,915.21 |
| Jun 30, 2016 | -3,118.23 |
| Jun 30, 2016 | -3,118.23 |